Trials / Completed
CompletedNCT04998487
A Single-Dose Study of LY3471851 in Healthy Participants
A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Nektar Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 64 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to estimate how much LY3471851 gets into the blood stream and how long it takes the body to remove it when administered under the skin in healthy participants. The study will also evaluate the safety and tolerability of LY3471851. The study is expected to last up to 87 days for each participant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3471851 | Administered SC. |
Timeline
- Start date
- 2021-08-16
- Primary completion
- 2022-07-06
- Completion
- 2022-07-06
- First posted
- 2021-08-10
- Last updated
- 2023-11-18
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04998487. Inclusion in this directory is not an endorsement.